News
China Ticks BeiGene PD-1, Can Novartis Bloom In US, Europe
Last year, Novartis chose to purchase its way into the arena after the failure of its PD-1/L1 candidate, spartalizumab. So it reached a deal with China's BeiGene, paying $650 million up front and promising $1.55 billion in milestone payments in...
News
Kings College Uses COVID-19 Tech To Treat Heart Attacks
King's College London, a public research university, is using messenger RNA (mRNA) technology to battle the physiological effects of cardiac arrest in the hopes of developing the world's first heart attack treatment. The technology has the ability to reverse...
News
Indian Pharma Must Aim Generics- Commerce Industry Minister
To become self-reliant, Union Commerce and Industry Minister of India, Piyush Goyal advised the domestic pharmaceutical sector to develop its generic medicine segment and provide greater synergy between input and output of products. Goyal, speaking at an event organised by the...
News
Bora Pharmaceuticals to expand operations with $10m+ investment
Fast-growing contract development and manufacturing organization (CDMO) BORA Pharmaceuticals, has announced a planned investment of $10 million to expand its Oral Solid Dose capabilities across facilities in Zhunan, Taiwan and Mississauga, Ontario.
The company’s CEO, Bobby Sheng, said the expansion,...
News
More COVID Cases In Shanghai Lead To Stiffer City-Wide Bans
On April 16th, Shanghai reported a new high for symptomatic COVID-19 cases, while other cities throughout China tightened controls as the country continued its "dynamic clearing" strategy to eradicate the highly communicable Omicron form.
A day before, the Zhengzhou Airport...
News
Is It Really Possible To Attain COVID-19 Herd Immunity?
The fresh, new, astonishingly efficient COVID-19 vaccines were rolling out across the US this time last year, injecting a strong note of confidence into the country's formerly stumbling pandemic response.
Hundreds of thousands of people were queuing up every day to get...
News
Covaxin Trials In The United States Have Been Put On Hold
The phase 2/3 clinical trials for Bharat Biotech's COVID-19 vaccine, Covaxin, in the United States have been halted by the US Food and Drug Administration. As per a press release from Ocugen Inc., Bharat Biotech's partner for Covaxin in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read